Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Hoffmann La RochefiledCriticalGenentech Inc
Priority claimed from PCT/US2015/017168external-prioritypatent/WO2015127405A2/fr
Publication of MA39300A1publicationCriticalpatent/MA39300A1/fr
Publication of MA39300B1publicationCriticalpatent/MA39300B1/fr
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Peptides Or Proteins
(AREA)
Abstract
L'invention concerne des anticorps bispécifiques anti-il-13/il-17, en particulier des anticorps anti-il-13, il-17/aa, af et ff anticorps et des méthodes d'utilisation de ceux-ci, y compris, sans limitation, des méthodes d'utilisation des anticorps bispécifiques anti-il-13/il-17 pour le traitement de l'asthme modéré à grave et/ou de l'asthme éosinophilique.
MA39300A2014-02-212015-02-23Anticorps bispécifiques anti-il-13/il-17 et leurs utilisations
MA39300B1
(fr)